Drug Target Review

NOVEMBER 30, 2023

Then I was approached to co-found AC Immune in 2003. Food and Drug Administration for our Alzheimer’s vaccine candidate, ACI-24.060. COVID-19 has shown the revolutionary impact of vaccines. Our investigational active immunisation therapies could potentially delay or perhaps even prevent the onset of clinical dementia symptoms.

Disease 95

Disease Therapies Laboratories Treatment 95

Drug Target Review

OCTOBER 4, 2023

10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects. Dual payload ADCs As effective as therapies have been in treating solid and haematological cancers, tumour heterogeneity and resistance remain major clinical challenges.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19. In the U.S.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

FEBRUARY 12, 2022

The approval extends the current indication in China as add-on therapy in adults and children aged five years and older with active systemic lupus erythematosus (SLE). 8) despite standard therapy. Benlysta, combined with standard therapy, is indicated in adult patients with active lupus nephritis. About lupus.

Production 52

Production Therapies Trials Disease 52

The Pharma Data

FEBRUARY 25, 2021

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

MARCH 26, 2021

The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE. positive anti-dsDNA and low complement) despite standard therapy. positive anti dsDNA and low complement) despite standard therapy. About the BLISS-LN study.

Therapies 52

Therapies Treatment Disease Vaccine 52

Codon

DECEMBER 17, 2023

A first draft of the human genome was completed in 2003. At least six CAR-T cancer therapies have now garnered F.D.A. Laundry may not be as immediately headline-grabbing as new cancer therapies, but it provides a concrete and ingenious solution to a demonstrable need. Mechanisms: Biotechnology shouldn’t be a mystery.

Engineering 52

Engineering Molecular Biology Doctors DNA 52